<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) is a very aggressive subtype of non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> that occurs with higher frequency in patients with HIV/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Patients with HIV-related <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> (HIV-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) are usually treated with high-intensity, multi-agent chemotherapy regimens </plain></SENT>
<SENT sid="2" pm="."><plain>The addition of the monoclonal antibody Rituximab to chemotherapy has also been studied in this setting </plain></SENT>
<SENT sid="3" pm="."><plain>The potential risks and benefits of commonly used regimens are reviewed herein, along with a discussion of controversial issues in the practical management of HIV-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>, including concurrent anti-retroviral therapy, treatment of relapsed and/or refractory disease, and the role of stem cell transplantation </plain></SENT>
</text></document>